AU · rank #1 · 2026-09-04
SNT
GPW · PLN · $742M (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.234 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$2.35 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) | — |
| Analyst upside Consensus target $373.00 | +15.4% |
| Momentum acceleration 3-month minus 12-month momentum. | +6.61% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.40 |
| Gross margin TTM | +23.5% |
| 52w high | $398.40 |
| Market cap (USD) | $742M |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Synektik is a Polish integrated healthcare group combining radiopharmaceutical manufacturing, medical imaging equipment distribution, and proprietary medical IT software serving oncology, cardiology, and neurology customers.
Rationale
All three covering analysts revised EPS upward in lockstep (100% revision agreement, +PLN 2.35 over 30 days) against a backdrop of genuine fundamental acceleration — Q3 FY2025/26 revenue nearly doubled YoY — making the 15.4% analyst upside and strong buy consensus (4.4/5) credible rather than sentiment-only.
Material risks
- 1High analyst target dispersion of 25.7% across only three analysts means the consensus price target is statistically fragile — a single estimate revision could materially reprice the upside signal that drives this screen.
- 2Polish public healthcare budget dependency is acute: equipment and radiopharmaceutical revenues lack disclosed long-term take-or-pay contracts, so any capex freeze in the Polish NFZ (National Health Fund) cycle would directly compress the revenue run-rate underpinning the EPS revisions.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 3 of 3 voted to proceed.